Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' reply

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
Volume38
Issue number5
Pages (from-to)552-3
Number of pages2
ISSN0269-2813
DOIs
Publication statusPublished - Sep 2013

ID: 42660506